Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 27, 2026SHILAP Revista de lepidopterologíaOpen Access

Chidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed/refractory acute myeloid leukemia: a single-center case series

View Full Paper
Ask AI
Bookmark
Share

Authors

QLQing LiJJJie JiYWYu Wu

Discussion

Loading...

Member takes

Overview

Case series shows promising remission rates in relapsed/refractory acute myeloid leukemia, indicating effective treatment options.

Key Points

  • To evaluate the effectiveness and tolerability of a combination therapy in patients with relapsed/refractory acute myeloid leukemia.
  • Case series involving three patients with relapsed/refractory AML
  • Treatment with chidamide, decitabine, venetoclax, and low-dose cytarabine
  • Assessment of remission status and adverse events after one cycle of treatment
  • All three patients achieved complete remission after treatment
  • Two patients attained minimal residual disease negativity
  • Adverse events were manageable, primarily cytopenias and infections

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69a1344fed1d949a99abe1d9https://doi.org/10.3389/fonc.2026.1760614
View Full Paper
Ask AI
Bookmark
Share